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ABSTRACT: Background: The Progressive Supra-
nuclear Palsy Rating Scale is a prospectively validated
physician-rated measure of disease severity for progressive
supranuclear palsy. We hypothesized that, according to
experts’ opinion, individual scores of items would differ in rel-
evance for patients’ quality of life, functionality in daily living,
and mortality. Thus, changes in the score may not equate to
clinically meaningful changes in the patient’s status.
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Objective: The aim of this work was to establish a con-
densed modified version of the scale focusing on mean-
ingful disease milestones.
Methods: Sixteen movement disorders experts evalu-
ated each scale item for its capacity to capture disease
milestones (0 = no, 1 = moderate, 2 = severe mile-
stone). Items not capturing severe milestones were
eliminated. Remaining items were recalibrated in pro-
portion to milestone severity by collapsing across
response categories that yielded identical milestone
severity grades. Items with low sensitivity to change
were eliminated, based on power calculations using
longitudinal 12-month follow-up data from 86 patients
with possible or probable progressive supranuclear
palsy.
Results: The modified scale retained 14 items (yielding 0–2
points each). The items were rated as functionally relevant
to disease milestones with comparable severity. The modi-
fied scale was sensitive to change over 6 and 12 months
and of similar power for clinical trials of disease-modifying
therapy as the original scale (achieving 80% power for two-
sample t test to detect a 50% slowing with n = 41 and
25% slowing with n = 159 at 12 months).
Conclusions: The modified Progressive Supranuclear Palsy
Rating Scale may serve as a clinimetrically sound scale to
monitor disease progression in clinical trials and routine. ©
2021 International Parkinson and Movement Disorder Society
Key Words: progressive supranuclear palsy; rating
scale; clinical meaningfulness; sensitivity to change
Progressive supranuclear palsy (PSP) is a sporadic
neurodegenerative disease with aggregation of
hyperphosphorylated 4-repeat tau isoforms in neurons,
astrocytes, and oligodendrocytes.1 Clinically, PSP pre-
sents with a spectrum of symptoms, including parkin-
sonism, ocular motor dysfunction, postural instability,
frontal lobar dysfunction, and bulbar signs, including
dysarthria and dysphagia.2
The Progressive Supranuclear Palsy Rating Scale
(PSPRS) has been developed to quantify the presence
and progression of these symptoms.3 The PSPRS is a
physician-rated measure of 28 items allocated into six
categories: daily activities (by history), mentation, bul-
bar, ocular motor, limb motor, and gait/midline exam
disturbances (by examination). Raters assign 0 to 2 or
0 to 4 points for each item, yielding a total PSPRS score
range of 0 to 100 points.3
The scale has been used as the primary outcome mea-
sure in numerous clinical trials and observational stud-
ies, in part because it generates reproducible annual
score changes across a wide range of disease severity
and time, and in multiple countries, enabling multicen-
ter trials with achievable group sizes.4-6
The PSPRS was developed as a tool for clinicians to
monitor a patient’s condition in a standard healthcare
setting and not primarily as a state measure for research
that would be sensitive to a progression over a short
period. Moreover, some important aspects of PSP are
addressed by more than one item, placing more weight
on the corresponding deficits.3 However, as an outcome
measure for interventional trials, recent evaluations
identified opportunities for improvement of the PSPRS;
for example, (1) not all items are considered to reflect
clinically meaningful aspects of the disease or clinically
meaningful milestones; (2) not all items contribute the
same maximum scores (range, 2–4); (3) some items
may capture related and overlapping features, thus con-
veying multiple scores for reaching only one clinical
milestone; (4) different items vary greatly in their sensi-
tivity to change over typical trial durations (12–
18 months); and (5) some items and their scores are not
sensitive to change, thus conveying no score changes
despite overall clinical disease progression. A previous
clinimetric analysis of the motor domain of the PSPRS
suggested removal of the PSPRS items limb dystonia,
tremor, and dysphagia for improved internal consis-
tency of the scale.7
We aimed to create a condensed and modified version
of the PSPRS (mPSPRS) by retaining items that report
clinically meaningful disease milestones according to
experts and by eliminating those with insufficient sensi-
tivity to change and conceptually redundant items. The
retained items were recalibrated against a semiquantita-
tive milestone severity grading. These measures aimed
to ascertain that comparable mPSPRS scores would rep-
resent comparable functional impact for different
patients, regardless of the items these scores had been
obtained in.
Materials and Methods
The mPSPRS was established by a stepwise process
that consisted of (1) semiquantitative evaluation of
the PSPRS items by movement disorder experts with
regard to representation of disability milestones from
their point of view, (2) elimination of PSPRS items
that depict only mild or moderate disability mile-
stones, (3) calibration of the retained items against
the milestone severity grading, (4) elimination of
items that proved to be insensitive to detect change
over a 12-month observation period, and (5) elimina-
tion of conceptually redundant items. This process is
shown as a flow chart in Supporting Information
Figure S1.
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Ethics
Data of participants of the TAUROS trial4 were
included in our analysis. All participants of the
TAUROS trial signed an informed consent for the reuse
of their data within the framework of the present study.
The TAUROS study protocol was approved by each
local ethics committee at each of the 24 TAUROS trial
site centers in the United Kingdom, Spain, Germany,
and the United States.4
Expert Evaluation of PSPRS Items With Regard
to Disease Milestones
Sixteen PSP experts from the International Parkinson
and Movement Disorder Society—European Section
evaluated each PSPRS item for whether, in their opin-
ion, reaching a particular score would indicate a clini-
cally meaningful disability milestone for the patient
(not necessarily for the caregiver) as a result of
impaired quality of life, reduced functionality in activi-
ties of daily living, or mortality risk, that is, how the
patient feels, functions, or survives. Every expert rated
every response category of each PSPRS item with
0 points (no milestone), 1 point (moderate milestone),
or 2 points (severe milestone). The assessments of the
experts were averaged, and a milestone grade was
attributed to each response category as follows: mean
value 0 to 0.5 point = no milestone (grade 0); mean
value >0.5 to 1.5 points = moderate milestone (grade
1); and mean value >1.5 to 2.0 points = severe mile-
stone (grade 2). “Clinical meaningful milestones” were
defined as milestones with relevance for the patient’s
quality of life, functionality in daily activities, and mor-
tality, as rated by expert physicians.
Elimination of Items Capturing No Severe
Milestone
To focus the scale on clinically meaningful features
according to experts, we eliminated items that did not
yield a mean milestone grade of 2 in any response
category.
Calibration Against Milestone Severity
To establish the same score range and proportionality
with milestone severity grades for each PSPRS item, we
collapsed response categories yielding the same milestone
grades into joint categories, generating three response cat-
egories for all PSPRS items (grade 0 = no milestone; grade
1 = moderate milestone; grade 2 = severe milestone).
Elimination of Items Insensitive to Change at
52-Week Follow-Up
Data from participants of the TAUROS trial with a
clinical diagnosis of possible or probable PSP
according to the National Institute of Neurological
Disorders and Stroke and the Society for PSP
(NINDS-SPSP) were available.2,4,8 Patients in both
the placebo and active treatment arms were consid-
ered, because there were no significant differences in
any of the examined parameters between the groups.
For the elimination of items insensitive to change,
only participants with baseline and 52-week follow-
up data per protocol were included in this analysis.
Power calculations for the individual PSPRS items in
their original and recalibrated form were performed,
as described previously by Stamelou et al.,6 to esti-
mate their sensitivity to detect change. Standardized
effect sizes were calculated from mean and standard
deviation (SD) of the annual changes. For the sample
size calculations, we used two-sample t tests and
Mann–Whitney U tests to detect 50%, 40%, 30%,
25%, and 20% change from natural disease progres-
sion in a 52-week follow-up.6,9,10 Bootstrapped confi-
dence interval was calculated for mean and
standardized effect sizes.11,12 Items with insufficient
sensitivity to change after 52 weeks with a standard-
ized effect size of <0.25 were eliminated. The thresh-
old of <0.25 was based on a pragmatic post hoc
decision to generate a balance between good sensitiv-
ity to change and retention of items to cover the
broad spectrum of disease aspects.
Elimination of Conceptually Redundant Items
To avoid duplicate scoring for the same clinical fea-
tures, we eliminated items that capture conceptually
closely related aspects of the disease, prioritizing those
items yielding higher milestone grading and higher stan-
dardized effect sizes.
Comparison of the PSPRS and the mPSPRS
To compare the sensitivity to change of the original
PSPRS versus the mPSPRS, we performed power calcu-
lations in the TAUROS study population described ear-
lier. To analyze sensitivity to change at 52-week follow-
up, we included data from 86 participants of the
TAUROS trial, which had baseline and 52-week
follow-up data per protocol.4 To analyze sensitivity to
change at 26-week follow-up, we included data from
113 participants. For correlation analysis of the PSPRS
and the mPSPRS, we used the model of linear
regression.
Power Calculation of mPSPRS in Confirmatory
PSP Cohorts
With independent data from two German observa-
tional PSP cohorts (ProPSP and DescribePSP), we per-
formed confirmatory power calculations.
The DescribePSP study, coordinated by the German
Center for Neurodegenerative Diseases, and the ProPSP
study, coordinated by the German Parkinson and
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Movement Disorders Society, both use the Movement
Disorder Society diagnostic criteria for PSP for inclu-
sion of participants.2
To analyze effect sizes of the mPSPRS items, we
included 45 patients enrolled in DescribePSP and
ProPSP with a complete dataset at baseline and at a first
follow-up visit between 36 and 60 weeks.
Patient Survey on the Clinical Meaningfulness
of the PSPRS Items
We conducted an exploratory, anonymous survey
among patients with PSP to assess the patients’ percep-
tion of the clinical meaningfulness of the PSPRS. The
patients were asked to rate each response category of
each item of the PSPRS with regard to their perceived
clinical meaningfulness (impact on quality of life, func-
tionality in daily living, and mortality) with the same
grading as described earlier for the experts. Because we
conducted the survey in Germany, we used a PSPRS
version translated into German lay language. Patients
were also asked to provide age, sex, disease duration,
and PSP phenotype, if known.
Results
Expert Milestone Ratings
In the experts’ milestone ratings, seven items of the
PSPRS reached a mean value of ≤1.5 points in all
response categories and, therefore, were considered as
not clinically meaningful, by failing to reflect severe dis-
ease milestones according to the experts (Supporting
Information Table S1). Those items were eliminated
from the PSPRS (Item 2: Irritability; Item 7: Sleep diffi-
culty; Item 11: Grasping/imitative/utilizing behavior;
Item 16: Voluntary left and right saccades; Item 20:
Finger tapping; Item 21: Toe tapping; Item 23: Postural
kinetic or rest tremor). We retained the remaining
21 items, yielding a mean milestone grade of 2 (severe
milestone) for the mPSPRS.
Calibration Against Milestone Severity
The remaining 21 items were recalibrated against the
milestone severity grading by collapsing categories
yielding the same milestone grades, as shown in
Supporting Information Table S2.
Elimination of Items Insensitive to Change at
52-Week Follow-Up
Data of 148 patients with PSP from the placebo or
active arms of the TAUROS trial were available.4
Eleven patients with different conditions at baseline
interfering with the per-protocol clinical evaluation and
51 patients who terminated prematurely during the trial
without a 52-week follow-up assessment were excluded.
Thus, PSPRS baseline and follow-up data of 86 patients
(37 females, 43%; 49 males, 57%) with unequivocal clini-
cal diagnosis and no major protocol violation were avail-
able for the current analysis. Their age (mean ± SD) at the
onset of PSP was 64.8 ± 7.1 years, their age at baseline
was 67.8 ± 6.8 years, and the disease duration was
3.0 ± 2.6 years.
Results of the power calculation for the individual
21 retained and recalibrated PSPRS items (Supporting
Information Table S2) demonstrated large variability in
the standardized effect sizes, ranging from 0.182 (Item
22: Apraxia of hand movement) to 0.800 (Item 25:
Arising from a chair). For comparison, sensitivity to
change of the original PSPRS items before recalibration
is shown in Supporting Information Table S1.
Based on the pragmatic threshold (<0.25), we elimi-
nated six items because of insufficient sensitivity to
change from the recalibrated PSPRS (Item 1: With-
drawal; Item 8: Disorientation; Item 9: Bradyphrenia;
Item 18: Limb rigidity; Item 19: Limb dystonia; Item
22: Apraxia of hand movement).
Elimination of Conceptually Redundant Items
To avoid redundancy within the scale, Item 14 was
removed (voluntary upward command movement)
because it covered similar functional concepts as Item
15 (voluntary downward command movement) and
had worse sensitivity to change.
In total, we removed 14 items from the PSPRS
(7 items because of insufficient milestone coverage,
6 items because of insufficient sensitivity to change, and
1 because of conceptual redundancy). Fourteen items
yielding 0 to 2 points each, reaching a maximum score
of 28 points and distributed into five categories [daily
activities (by history), mentation, bulbar, ocular motor,
and gait/midline examination], were retained. The final
mPSPRS, including milestone ratings and sensitivity to
change for each item, is shown in Table 1.
Sensitivity to Change of mPSPRS Versus
PSPRS
At 52-Week Follow-Up
At 52-week follow-up, the total PSPRS score yielded
an annual change of 11.1 points (SD ± 8.5) in our sam-
ple of patients with PSP, corresponding to 11.1%, in
accordance with former studies.3,6,13 The total mPSPRS
score yielded an annual change of 4.8 points
(SD ± 3.8), corresponding to 17.1%. The sensitivity to
change (ie, standard effect sizes and required sample
sizes to detect an effect of an intervention in a 52-week
follow-up therapeutic trial) of the total PSPRS score
and the total mPSPRS score were similar (Table 2).
A strong positive linear correlation was evident
between the mPSPRS total score and the PSPRS total
score at baseline and at 52-week follow-up (Fig. 1A), as
4 Movement Disorders, 2021
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well as between the total score changes of the mPSPRS
and the PSPRS over 52 weeks (Fig. 1B).
At 26-Week Follow-Up
At 26-week follow-up, the PSPRS and the mPSPRS
were able to measure disease progression in our sample
of patients with PSP. The total PSPRS score yielded a
6-month change of 5.6 points (SD ± 7.1) in our sample
of patients with PSP, corresponding to 5.6%. The total
mPSPRS score yielded a 6-month change of 2.2 points
(SD ± 3.0), corresponding to 7.9%. The PSPRS
required n = 103 for a two-sample t test per group to
detect a 50% slowing in a therapeutic trial. Similarly,
the mPSPRS required n = 118 to detect a 50% slowing
(Table 3).
Power Calculation of mPSPRS in the
Confirmatory PSP Cohort
In the power calculation with independent data from
45 patients of the observational PSP cohorts (ProPSP
and DescribePSP), the mPSPRS required slightly higher
sample sizes for a therapeutic trial to detect 50%
change (Supporting Information Table S3). However,
the standardized effect sizes of the mPSPRS correlated
with the standardized effect sizes from the TAUROS
trial (R = 0.54) (Supporting Information Table S4). Dis-
ease duration of DescribePSP and ProPSP participants
was significantly shorter than that of the TAUROS par-
ticipants (Supporting Information Table S5). Moreover,
these patients presented with a broader spectrum of
clinical phenotypes (Supporting Information Table S5).
Clinimetric Properties
Cronbach’s alpha of 0.78 proved good internal con-
sistency of the 14 mPSPRS items. The mPSPRS items of
the subscale “gait,” including “arising from chair,”
“gait,” “postural instability,” and “sitting down” corre-
lated best with the overall score (Supporting Informa-
tion Table S6).14 A floor effect was observed in the
categories “bulbar,” “gait,” “mentation,” and “ocular”
of the mPSPRS, but neither floor nor ceiling effect were
observed for the mPSPRS total score (Supporting Infor-
mation Table S7). The 14 items of the mPSPRS
explained 56% of the scale variance in a principal com-
ponent analysis using varimax rotation for discriminant
validity (Supporting Information Table S8).14
Patient Survey on the Clinical Meaningfulness
of PSPRS Items
Nine patients with PSP (56% male; mean disease
duration of 3.0 ± 0.7 years; four PSP-RS, one other
phenotype, four with unspecified phenotype) partici-
pated in the anonymous survey. Overall, the patients’
ratings of the individual PSPRS response categories cor-
related well with the experts’ ratings (Pearson’s
R = 0.8528, P < 0.00001; Fig. 2A). The mean patients’
and experts’ ratings matched in all but four PSPRS
items with regard to classification of the highest
response category into severe milestone (>1.5 points) or
not (Fig. 2B). These four diverging items were “sleep
difficulty,” “emotional incontinence,” “voluntary left
and right saccades,” and “tremor in any part.” Five
items of the PSPRS were not considered to report severe
milestones by the patients (Fig. 2B). These were
“irritability,” “emotional incontinence,” “grasping/imita-
tive/utilizing behavior,” “finger tapping,” and “toe tap-
ping.” All items incorporated into the mPSPRS were
formally considered to report severe milestones (>1.5
points) by the patients; only “emotional incontinence”
scored slightly lower (1.44 ± 0.88).
Discussion
Our main objective was to create a condensed version
of the PSPRS, with items that reflect the wide range of
FIG. 1. Linear regression of Progressive Supranuclear Palsy Rating
Scale (PSPRS) total scores against modified PSPRS (mPSPRS) total
scores. (A) Linear regression of PSPRS total scores against mPSPRS
total scores at baseline and at 52-week follow-up. Pearson’s correlation
at baseline: n = 137, R = 0.91, P < 0.0001; Pearson’s correlation at
52-week follow-up: n = 86, R = 0.91, P < 0.0001. (B) Linear regression
of PSPRS against mPSPRS score changes over 52 weeks. Pearson’s
correlation: n = 86, R = 0.83, P < 0.0001. [Color figure can be viewed at
wileyonlinelibrary.com]
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functional disabilities in patients with PSP. Our step-
wise process reduced the 28 PSPRS items to 14 as the
“modified PSPRS.” The mPSPRS reliably measures func-
tionally relevant disease progression in PSP and cap-
tures disability milestones. The mPSPRS is suitable for
both cross-sectional and longitudinal study designs.
The majority of experts who performed the milestone
ratings were members of the European Movement Dis-
order Society. Their ratings indicated that the items of
the PSPRS have different clinical relevance for patients.
Ranking the items into clinically meaningful milestone
grades (no, moderate, or severe) as rated by the experts
was the first approach to obtain a better tool to picture
disease progression and functionality with regard to
quality of life, activities of daily living, or mortality for
patients with PSP. Furthermore, the PSPRS contains
unevenly distributed scores for response categories,
ranging from 0 to 2 as well as 0 to 4 points.3 The
recalibrated mPSPRS enables three equally distributed
response categories and the same score range (0–2
points) for all items. This offers the advantage of pro-
ducing equal impact of each scale item on the total
score, thus improving comparability of the scale items,
simplifying the rating task, and consuming less time.
The sensitivity to change of the mPSPRS was only
marginally lower than that of the PSPRS (Table 2),
indicating that the modifications in practical terms did
not reduce the metric power of the PSPRS. The calcu-
lated sample sizes required to detect a 50% change of a
1-year follow-up therapeutic trial for the mPSPRS were
similar and very close to those of the PSPRS (Table 2).
In power analysis, the 28 items of the PSPRS differed
FIG. 2. Milestone ratings of Progressive Supranuclear Palsy Rating Scale (PSPRS) items by patients and experts. (A) Scatterplot of mean milestone rat-
ings of the individual response categories of the 28 PSPRS items by patients versus experts with linear regression line (Pearson’s R = 0.8528,
P < 0.00001). (B) Bar chart of the mean (± standard deviation) milestone ratings by patients and experts for the highest response categories in the 28
PSPRS items: 1 = Withdrawal; 2 = Irritability; 3 = Dysphagia for solids; 4 = Using knife and fork, buttoning clothes, washing hands and face; 5 = Falls;
6 = Urinary incontinence; 7 = Sleep difficulty; 8 = Disorientation; 9 = Bradyphrenia; 10 = Emotional incontinence; 11 = Grasping/imitative/utilizing
behavior; 12 = Dysarthria; 13 = Dysphagia; 14 = Voluntary upward saccades; 15 = Voluntary downward command movements; 16 = Voluntary left and
right saccades; 17 = Eyelid dysfunction; 18 = Limb rigidity; 19 = Limb dystonia; 20 = Finger tapping; 21 = Toe tapping; 22 = Apraxia of hand movement;
23 = Tremor in any part; 24 = Neck rigidity or dystonia; 25 = Arising from chair; 26 = Gait; 27 = Postural stability; and 28 = Sitting down. Bold items are
included into the mPSPRS. Items rated >1.5 points were considered as severe milestone. [Color figure can be viewed at wileyonlinelibrary.com]
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significantly with regard to their standardized effect size
(range, −0.047 to 0.875). The selected 14 items of the
mPSPRS demonstrated more balanced standardized
effect sizes (range, 0.285 to 0.800) and sample sizes.
This finding does not oppose the purpose of the
PSPRS, as the authors of the PSPRS attempted to
include all important areas of clinical impairment in
PSP, acknowledging that some items are probably less
relevant for clinical impairment in PSP.3
Expectedly, the PSPRS total score yielded lower effect
sizes for a 26-week observation period than for a
52-week period. The same was true for all PSPRS cate-
gories (bulbar, gait, history, mentation) but the limb
score category, in which the effect size was higher in
the shorter observation period in this dataset, because
raters had scored higher values at 26 weeks compared
with 52 weeks on average. Because symptoms in PSP
are progressive without remissions, this observation
provides another argument not to include the limb
score category items in the mPSPRS.
The selection process of the 14 items was our
approach to retain items that report clinically meaning-
ful disease milestones for patients with PSP, according
to the experts. We used the judgment of physicians with
longstanding experience in the care for patients with
PSP to rate the clinical meaningfulness of each scale
item of the PSPRS and did not take into account
patients’ and caregivers’ opinions when designing the
scale. However, a general shortcoming in designing a
measure for clinically meaningful disability milestones
is the difficulty of defining them, that is, which disabil-
ities and to what extent they are meaningful to patients.
This would be especially important for history and
mentation aspects of the PSPRS, while taking into
account that patients may lack insight into their func-
tional deficits. This symptom (“anosognosia”) is well
studied in Alzheimer’s disease15 and also has been
shown in PSP.16 The perception of the patients’ care-
givers is also only a surrogate for the patients’ percep-
tion, and there remains the challenge of defining and
identifying comparable caregivers with regard to prox-
imity to subjective experiences and perceptions and
judgments of the patient. In the small exploratory
patient survey on the PSPRS items, we found that all
but one item incorporated into the mPSPRS were con-
sidered severe disease milestones by the patients. Only
the item “emotional incontinence” scored slightly below
the formal threshold of >1.5. However, further studies
with higher case numbers are required to analyze the
patients’ and caregivers’ perception of the severity and
functional relevance of the PSPRS and mPSPRS items,
taking into account covariables, such as disease stage,
cognitive impairment, and social support.
Some items of the mPSPRS rely on recent history,
including “dysphagia for solids,” “using knife and fork,
buttoning clothes, washing hands and face,” “falls,” and
“urinary incontinence.” For these, the caregiver should
be the primary source of information for all visits to
ensure consistency. The patient’s opinion should also be
considered, and the clinician should make the final rat-
ing based on his/her judgment when the caregiver and
patient cannot come to a resolution on their own, as
was also recommended for the PSPRS.17
Longitudinal studies with patients with PSP will have
to cope with the high dropout rate caused by rapid dis-
ease progression and severe physical disability previ-
ously reported.6 Our analyses contained only patients
who completed the trial and who met prespecified per-
protocol criteria of the TAUROS trial.
For planning of a trial, of course, our proposed
power-calculation-based case numbers represent final
numbers that need to be available for analysis. Thus,
any planned trial will need to adjust the number of
patients to be recruited allowing to compensate for
expected dropout rates. Dropout rates within
12 months in prior trials were between 23% in the
Davunetide Trial5 and 35% in the TAUROS trial.4
A shorter trial duration could reduce dropout, as can
be observed in the TAUROS trial: Although the drop-
out rate at 52-week follow-up was 41%, it was only
24% at 26-week follow-up. We demonstrated that the
mPSPRS could also depict changes within shorter time
ranges, such as 26 weeks (Table 3).
Although cognitive and behavioral problems play a
major role in PSP,18 the mPSPRS contains only emo-
tional incontinence in the mentation category. We
selected this item because expert milestone rating for
emotional incontinence was similar to bradyphrenia
and disorientation; however, the item emotional incon-
tinence showed higher sensitivity to change after rec-
alibration. Thus, the mPSPRS does not account for
other items of mentation, including disorientation,
bradyphrenia, and grasping/imitative/utilizing behavior,
and this area of disability might be underrepresented
for a clinical routine setting.
Further evaluation of the clinimetric properties of the
mPSPRS with regard to internal consistency, reproduc-
ibility, and validity of the mPSPRS is warranted.
Our power analysis was performed in patients with
PSP with a clinical diagnosis of possible or probable
PSP according to the NINDS-SPSP diagnostic criteria,8
which primarily allow for a diagnosis of PSP with
Richardson’s syndrome (PSP-RS) and not the variant
PSP syndromes.19 Variant PSP syndromes, as part of
the new MDS-PSP criteria,2 show different progression
patterns. A recent publication demonstrated that
patients with PSP-RS progressed significantly faster in
the PSPRS than patients with PSP parkinsonism.20
Thus, sensitivity to change of the mPSPRS might differ
when including more patients with variant PSP syn-
dromes. Yet, considering previous literature,18,20 the
selected items (mostly those related to dysphagia, eye
Movement Disorders, 2021 11
M O D I F I E D P S P R A T I N G S C A L E
movements, and axial problems) still could be valuable
in variant PSP syndromes as “turning point” clinical
features that mark the change from slow to more
aggressive progression at a certain disease stage.
In our confirmatory analysis with an independent
cohort of patients with PSP with a broader range of
PSP phenotypes, the mPSPRS required higher sample
sizes to detect change, which might relate to the
broader inclusion criteria for the confirmatory com-
pared with the exploratory cohort. However, the stan-
dardized effect sizes correlated with those of the
TAUROS data. Prospective studies with larger case
numbers shall confirm or confute our findings.
We recommend that the mPSPRS should be pre-
ferred to measure treatment effects in disease-
modifying trials, because the mPSPRS showed good
sensitivity to change and is short and easy to apply.
Compared with the PSPRS, the mPSPRS takes less
time, and short scales to monitor disease progression
play an important role in clinical care.21,22 If a more
comprehensive reporting of the spectrum of PSP-
related symptoms is needed, for example, in observa-
tional natural history studies, we recommend using the
full PSPRS, because it comprises symptoms more com-
prehensively than the mPSPRS.
With these caveats, the mPSPRS shows similar sensi-
tivity to change compared with the PSPRS and can be
completed in less time. The selected items cover the
most important spectrum of symptoms for patients with
PSP, and their milestone scores imply clinically mean-
ingful changes as evaluated by experts. Thus, the
mPSPRS may serve as a clinimetrically suitable scale to
monitor progression of disease milestones in PSP.
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